How Conjunctival Inflammation and Fibrosis Shape oGVHD
The conjunctiva is easy to overlook, but in oGVHD it can be central to disease progression.
The conjunctiva is the membrane that lines the inside of the eyelids and covers part of the white surface of the eye. It helps maintain ocular surface health, supports immune defense, and contributes to tear-film stability. Conjunctival goblet cells produce mucins that help tears spread across the eye and adhere to the ocular surface.
In oGVHD, the conjunctiva may become inflamed. Over time, chronic inflammation can contribute to scarring and fibrosis. Fibrosis is the formation of scar-like tissue that can change normal tissue structure and function. In the eye, conjunctival fibrosis can interfere with ocular surface smoothness, eyelid movement, tear distribution, and comfort.
This is one reason oGVHD can be more serious than ordinary dryness. The disease can affect the tissues that maintain the surface, not only the volume of tears bathing the surface. If the conjunctiva becomes scarred or goblet cell support is reduced, the tear film may become unstable and the cornea may become more exposed to friction and injury.
Patients may experience redness, irritation, foreign body sensation, pain, light sensitivity, mucus, dryness, or fluctuating vision. These symptoms may overlap with dry eye, allergy, infection, medication effects, or environmental irritation. But in the transplant setting, persistent symptoms must be interpreted differently.
The conjunctiva is also important because scarring can become difficult to reverse. Once tissue architecture is altered, the clinical problem may become less about temporary irritation and more about long-term ocular surface maintenance. This is why early recognition matters.
For clinicians, conjunctival involvement is part of oGVHD assessment. Examiners may look for inflammation, scarring, lid margin changes, tear-film abnormalities, corneal staining, and other signs that help distinguish oGVHD severity and pattern.
For researchers, conjunctival inflammation and fibrosis raise important questions. Which biological pathways drive scarring? Can early inflammatory change predict later structural damage? Which biomarkers reflect active fibrotic disease? Which endpoints can measure tissue preservation?
For patients and advocates, the lesson is that oGVHD can alter the architecture of the eye surface. Symptoms after transplant should not be minimized simply because they sound like “dry eye.” The underlying process may involve immune-mediated injury, inflammation, and fibrosis.
Understanding the conjunctiva shifts the conversation from moisture alone to tissue health.
This article is for educational purposes only and is not medical advice.
Sources:
- Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full - Nassiri N, Eslani M, Panahi N, et al. “Ocular Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation.” Journal of Ophthalmic & Vision Research, 2013.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3957042/ - Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/
